Inception Return
(10/28/2013)
|
6.47 %
|
|
YTD Return
|
5.50 %
|
|
NAVPS
(9/11/2026)
|
$22.04
|
|
Change
|
$0.17 / 0.75 %
|
|
|
Growth of $10,000
(As of August 31, 2026)
|
|
MER
|
2.80 %
|
|
Assets ($mil)
|
$385.10
|
|
Rank (1Yr)
|
1029/1200
|
|
Std Dev (3Yr)
|
8.26 %
|
|
Volatility Ranking (3Yr)
|
4/10
|
|
RRSP Eligibility
|
Yes
|
|
Load
|
Choice of Front or No Load
|
|
Max Front End
|
5.00 %
|
|
Max Back End
|
5.50 %
|
|
Sales Status
|
Partially Open
|
|
|
Objective
The Fund seeks to provide a combination of income and capital appreciation by investing primarily in a diversified portfolio of dividend paying equity securities and fixed income securities.
|
Fund Manager
Manulife Investment Management Limited
Portfolio Manager
Christopher Chapman, Manulife Investment Management Limited
Sub-Advisor
Michael J. Mattioli, Manulife Investment Management (US) LLC
Daniel S. Janis III, Manulife Investment Management (US) LLC
Thomas C. Goggins, Manulife Investment Management (US) LLC
Dennis F. McCafferty, Manulife Investment Management (US) LLC
Emory (Sandy) W. Sanders, Manulife Investment Management (US) LLC
Manulife Investment Management (Europe) Limited
Kisoo Park, Manulife Investment Management (Hong Kong) Limited
|
|
Asset Allocation
(As of July 31, 2026)
|
Sector Allocation
(As of July 31, 2026)
|
Geographic Allocation
(As of July 31, 2026)
|
Top 10 Holdings
| Name | Asset | Sector | Geographic | Percent |
| Microsoft Corp | US Equity | Technology | United States | 3.10% |
| Amazon.com Inc | US Equity | Consumer Services | United States | 3.00% |
| KKR & Co Inc | US Equity | Financial Services | United States | 2.58% |
| Alphabet Inc Cl A | US Equity | Technology | United States | 2.46% |
| Taiwan Semiconductor Manufactrg Co Ltd - ADR | International Equity | Technology | Asia/Pacific Rim | 2.09% |
| Cheniere Energy Inc | US Equity | Energy | United States | 2.04% |
| UnitedHealth Group Inc | US Equity | Healthcare | United States | 1.82% |
| Broadcom Inc | US Equity | Technology | United States | 1.67% |
| Apple Inc | US Equity | Technology | United States | 1.63% |
| Thermo Fisher Scientific Inc | US Equity | Healthcare | United States | 1.59% |
Performance Data
(As of August 31, 2026)
|
|
Return (%)
|
Annualized Return (%)
|
|
Return
|
1
Mth
|
3
Mth
|
6
Mth
|
YTD
|
1
Yr
|
3
Yr
|
5
Yr
|
10
Yr
|
|
Fund
|
0.94
|
2.47
|
4.22
|
5.50
|
6.72
|
8.16
|
4.32
|
5.51
|
|
Benchmark
|
0.55
|
1.14
|
5.43
|
8.72
|
12.83
|
13.40
|
6.87
|
7.56
|
|
Quartile Ranking
|
1
|
1
|
2
|
3
|
4
|
4
|
3
|
2
|
|
Calendar Return (%)
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
|
Fund
|
2.87
|
11.07
|
13.18
|
-10.62
|
13.45
|
3.41
|
19.71
|
-10.78
|
8.91
|
8.87
|
|
Benchmark
|
10.42
|
17.48
|
11.69
|
-11.62
|
6.48
|
11.12
|
12.26
|
2.68
|
8.66
|
2.39
|
|
Quartile Ranking
|
4
|
3
|
1
|
2
|
1
|
4
|
1
|
4
|
1
|
1
|